Ovid Therapeutics Inc. OVID 深 滬

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Ovid Therapeutics announced that its management will participate in two upcoming investor conferences: the Oppenheimer CNS & Neuro-Muscular Summit on June 10 at 3:45 pm ET and the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15. Presentations will be available via webcast on the company’s website at investors.ovidrx.com, with an archived replay for 30 days post-event.

06-04 11:00

Ovid Therapeutics Expands Board, Appoints New Scientific Director

Ovid Therapeutics ( ($OVID) ) has shared an announcement. On May 29, 2026, Ovid...

06-03 21:51

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

Ovid Therapeutics Inc. announced the appointment of Dr. Anna Greka as a new Board member, effective June 15, 2026. Dr. Greka, a renowned physician-scientist and entrepreneur, will Chair the Science and Technology Committee and join the Compensation Committee. Her expertise in ion channel biology and therapeutic innovation will support Ovid's development of KCC2 activators and epilepsy programs.

06-03 11:00

Ovid Therapeutics Q1 EPS $(0.12) Misses $(0.11) Estimate

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 14.29 percent increase over losses of $(0.14) per share

05-12 19:21

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

05-12 11:00

Ovid Therapeutics Boosts Capital Through Warrant Exercises

The latest announcement is out from Ovid Therapeutics ( ($OVID) ). On April 17,...

04-20 20:52

美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价

今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元

04-16 10:14

美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价

今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元

04-10 18:27

HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $4

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $2 to $4.

04-09 19:32

美股牛股 | ALHC飙升16%，公司受益于CMS提高医疗保险支付额；潘兴广场拟高溢价收购环球音乐集团，UNVGY大涨13%

ALHC飙升16%，公司受益于CMS提高医疗保险支付额；潘兴广场拟高溢价收购环球音乐集团，UNVGY大涨13%；赫兹租车升逾10%，二手车价格上涨提升其车队投资回报率>>

04-08 19:09